Dicarboxylic acids are prominent features of several diseases, including Reye's syndrome and inborn errors of mitochondrial and peroxisomal fatty acid oxidation. Moreover, dicarboxylic acids are potentially toxic to cellular processes. Previous studies [Tonsgard, Mendelson & Meredith (1988 ) J. Clin. Invest. 82, 1567-1573 demonstrated that long-chain dicarboxylic acids have a single high-affinity binding site and between one and.three lower-affinity sites on albumin. Medium-chain-length dicarboxylic acids have a single low-affinity site. We further characterized dicarboxylic acid binding to albumin in order to understand the potential effects of drugs and other ligands on dicarboxylic acid binding and toxicity. Progesterone and oleate competitively inhibit octadecanedioic acid binding to the single high-affinity site. Octanoate inhibits binding to the low-affinity sites. Dansylated probes for subdomain 2AB inhibit dodecanedioic acid binding whereas probes for subdomain 3AB do not. In contrast, low concentrations of octadecanedioic acid inhibit the binding of dansylated probes to subdomain 3AB and 2AB. L-Tryptophan, which binds in subdomain 3AB, inhibits hexadecanedioic acid binding but has no effect on dodecanedioic acid. Bilirubin and acetylsalicylic acid, which bind in subdomain 2AB, inhibit the binding of medium-chain and long-chain dicarboxylic acids. Our results suggest that longchain dicarboxylic acids bind in subdomains 2C, 3AB and 2AB. The single low-affinity binding site for medium-chain dicarboxylic acids is in subdomain 2AB. These studies suggest that dicarboxylic acids are likely to be unbound in disease states and may be potentially toxic.
INTRODUCTION
Dicarboxylic acids (DCAs) are formed after the w-oxidation of monocarboxylic acids by a cytochrome P-450-coupled enzyme pathway (see review by Mortensen, 1984) . Although the formation of DCAs was described more than 50 years ago (Verkade et al., 1933) , their role in mammalian fatty acid metabolism is poorly understood. Only 5-10% of circulating non-esterified fatty acids in ketotic rats are metabolized through this pathway (Bjorkhem, 1978) . However, DCAs have recently been recognized to be a prominent feature of several diseases in humans (Tonsgard, 1986; Rocchiccioli et al., 1986; Vianey-Liand et al., 1987) . In Reye's syndrome as much as 55 % of the circulating non-esterified fatty acids are DCAs. In this illness 85-90 % of the DCAs are long chain, of length C14-C,8 (Tonsgard, 1986) . These long-chain DCAs are potentially toxic to mitochondrial function (Mortensen & Gregersen, 1982; Passi et al., 1984; Kimura, 1986) . Since alterations in mitochondrial structure and function are prominent features of both Reye's syndrome and Zellweger syndrome (Goldfischer et al., 1973; DeVivo, 1978; Kelley, 1983) , understanding the regulation of DCA metabolism may be important in these as well as other diseases where DCAs accumulate.
The binding of monocarboxylic fatty acids to albumin and the intracellular fatty acid-binding proteins modulates the transport and metabolism of these fatty acids. Moreover, binding of a potentially toxic ligand to albumin protects against the toxic effects of the ligand, since toxicity is proportional to the concentration of unbound ligand (Spector, 1975) . Our initial observations indicated that long-chain DCAs in patient serum exert toxic effects on isolated mitochondria even in the presence of defatted albumin, suggesting that DCAs are largely unbound in patients. In order to test this hypothesis, we examined the affinity and capacity of albumin for DCAs. We demonstrated that albumin has a single higheraffinity site for long-chain DCAs of Kd 1-2 /tM and between one and three lower-affinity binding sites of Kd 20-60 /SM, depending on the chain length of the DCA. Low concentrations of oleic acid displace long-chain DCAs from the higher-affinity albumin binding site; DCA is displaced from the lower-affinity sites only when the oleate/albumin ratio approaches 3: 1 (Tonsgard et al., 1988) . We undertook the present study to characterize further the DCA-binding sites on the albumin molecule in order to understand the potential effec*s of drugs and other ligands on DCA binding and toxicity.
EXPERIMENTAL Monocarboxylic and dicarboxylic acids
Unlabelled monocarboxylic acids and DCAs were from Sigma Chemical Co. (St. Louis, MO, U.S.A.), Applied Science (Warrenville, IL, U.S.A.), Foxboro Analabs (North Haven, CT, U.S.A.) and Ultra Scientific (North Kingston, RI, U.S.A.). The purity of the unlabelled acids was assessed by g.l.c. (Tonsgard, 1986) and was found to be at least 99.5 %. 3H-labelled dicarboxylic acids and [1-_4C]octanoic acid were from Amersham (Arlington Heights, IL, U.S.A.). The 3H-labelled dicarboxylic acids were prepared by Amersham by reaction with tritiated water at a very high specific radioactivity. The chemical purity of the labelled compounds was assessed by g.l.c. and found to be at least 970%. The radiopurity of the labelled compounds was assessed by t.l.c. (Tonsgard et al., 1988) and was at least 93.4 %.
Potassium salts of a mixture of labelled and unlabelled monocarboxylic acid or DCA were made as described previously (Tonsgard et al., 1988) .
Albumin
Essentially fatty acid-free (less than 0.005 %o, w/w) crystalline BSA was from Sigma Chemical Co. and further purified as described by Spector et al. (1969) . The monocarboxylic fatty acid content of the purified albumin was determined by g.l.c. as described previously (Tonsgard et al., 1988) and found to be less than 0.02 mol of fatty acid/mol of albumin.
Modification of albumin
Purified defatted albumin (0.2 mM) was acetylated with 1 mMacetylsalicylic acid in 0.10 M-sodium phosphate buffer at pH 6.8 and 7.6 as described by Hawkins et al. (1969) at 37 'C. The albumin solution was then dialysed for 48 h at 4 'C against multiple changes of 0.15 M-NaCl containing 0.01 M-sodium salicylate and then against 0.1 M-sodium phosphate buffer, pH 7.4. The albumin was then freeze-dried and stored at 4 'C. In other experiments, albumin was acetylated with acetic anhydrydride at pH 8.0 as described by Fraenkel-Conrat (1957) . Acylation of amino groups was assessed by the ninhydrin test (FraenkelConrat, 1957) . Thiol-group-modified BSA was purchased from ICN Biochemicals (Costa Mesa, CA, U.S.A.). The thiol groups were modified by reaction with L-cysteine (Miles Laboratories, Kankakee, IL, U.S.A.). The degree of thiol-group modification was determined to be at least 95 % as performed by the manufacturer.
Equilibrium dialysis
Binding of DCAs to defatted BSA was determined by using equilibrium dialysis as described previously (Tonsgard et al., 1988 (Moll & Rosenfield, 1977) . Although the amount of bound progesterone must be regarded as an approximation, equilibrium dialysis is the preferred technique for assessment of progesterone binding (Westphal, 1969) .
Competition experiments with octanoic acid were performed as described previously (Tonsgard et al., 1988) .
Bilirubin was obtained from ICN Biomedicals (Costa Mesa, CA, U.S.A.). Bilirubin was dissolved in dimethyl sulphoxide (4 mg/ml) and stored at -20 'C. On the day of the experiment the concentration of the bilirubin stock solution was checked spectrophotometrically at 455 nm (Tietz, 1976) . The bilirubin stock solution was then dissolved in 0.1 M-Na2CO3 containing 60 /tM-albumin. The bilirubin solution was then further diluted to a bilirubin concentration of 100 /tM and defatted albumin was added (final concentration 50 /M) (Tietz, 1976) . The final dimethyl sulphoxide concentration in the experiments was 0.5 %.
Bound and unbound bilirubin were separated by the use of 1 ml Sephadex G-25 spin columns described previously (Tonsgard et al., 1988 Fig. 1 ). Dansylglycine, dansylsarcosine, dansylproline and dansylglutamine were purchased from Sigma Chemical Co. With the exception of dansylglycine, the probes are believed to have a single binding site (Sudlow et al., 1975) . The probes were dissolved in warm methanol and buffer. The final concentration of methanol in the experiments was 0.1 %. A molar ratio of fluorescent probe to albumin less than 1:1 was used to ensure that most of the probe was bound, as described by Sudlow et al. (1976) . In experiments with dansylglycine the ratio of probe to albumin was 1:20, as described by Sudlow et al. (1976) , in order to focus on the principal dansylglycine-binding site. Control experiments in which various concentrations of DCA were incubated with dansyl probes in the absence of albumin demonstrated that the 1991 dansylated compounds only fluoresce when bound to albumin. Displacement of the probe was determined by comparing the fluorescence of the probe in the presence of albumin and in the absence of competitor to the fluorescence in the presence of albumin and various concentrations of DCA measured on a Perkin-Elmer LS-5B luminescence spectrometer with the excitation and emission wavelengths suggested by Sudlow et al. (1975 Sudlow et al. ( , 1976 . However, in some instances addition of DCA to solutions containing BSA and probe initially increased fluorescence. Therefore, in order to assess the binding of dansylamino acid and displacement by DCA, we also directly measured the displacement of dansylated amino acids by using equilibrium dialysis with 3H-labelled dansyl-amino acids and unlabelled DCAs. 3H-labelled dansyl-amino acids were synthesized as described by Oray et al. (1983) from L-[2,3,4,5-3H]proline and L-[G-3H]glutamine (Amersham) and dansyl chloride (Sigma Chemical Co.). The reaction products were identified and separated by h.p.l.c. after comparison with authentic standards. The concentrations of 3H-labelled dansyl-amino acids were determined spectrophotometrically by using the molar absorption coefficient e 4.5 x 10-3 M-1 cm-1.
Analysis of binding
Binding isotherms were analysed by the damping Gauss-Newton algorithm with the use of a non-linear leastsquares-fit computer program (Tonsgard et al., 1988 (Tonsgard et al., 1988) . We used the Akaike information coefficient to ascertain whether the best fit of the data could be obtained by assuming one, two or three classes of binding site (Yamaoka et al., 1981) .
RESULTS
Higher-affinity long-chaXn dicarboxylic acid-binding site Previous investigations demonstrated that albumin has at least two distinct classes of binding sites for DCAs (Tonsgard et al., 1988) . Long-chain DCAs have a single higher-affinity binding site and compete for one of the three subdomains that are the primary binding sites of long-chain monocarboxylic acids, subdomains IC, 2C and 3C ( Fig. 1) (Brown & Shockley, 1982) . We examined the effect of competition with the steroid progesterone in order to localize further the higher-affinity DCA-binding site. Progesterone binds to Trp-214 in subdomain 2C (Brown & Shockley, 1982; Swaney & Klotz, 1970 Vol. 276 inhibits dodecanedioic acid binding. When a single molecule of octanoic acid is bound to the BSA molecule, the binding of dodecanedioic acid is essentially eliminated (Table 1) . This confirms previous studies (Tonsgard et al., 1988) that suggested that the low-affinity binding site for medium-chain DCAs is in the subdomains that bind medium-chain-length monocarboxylic acids (lAB, 2AB and 3AB; Fig. 1 ).
We also examined the effect of bilirubin and tryptophan, which bind in subdomains 2AB and 3AB respectively (Brown & Shockley, 1982) , on dodecanedioic acid binding. When albumin is incubated with 100 /tM-bilirubin and various concentrations of dodecanedioic acid, 0.72 mol of bilirubin/mol of albumin is bound and 0.8 mol of dodecanedioic acid/mol of albumin is displaced (Table 1) . In contrast, L-tryptophan, which binds in subdomain 3AB (Brown & Shockley, 1982) , has no effect on dodecanedioic acid binding (Table 1) .
The drug-binding sites of albumin in subdomains 2AB and 3AB have been characterized by their affinity for different dansylated amino acids (Sudlow et al., 1975 (Sudlow et al., , 1976 . Dodecanedioic acid inhibits dansylglycine binding in subdomain 2AB but has little effect on dansylsarcosine binding in subdomain 3AB (Fig. 3) . These studies support the results of the competition studies with bilirubin and tryptophan, indicating that dodecanedioic acid binds in subdomain 2AB.
Localization of the lower-affinity long-chain dicarboxylic acidbinding sites Previous studies (Tonsgard et al., 1988) suggested that the medium-chain monocarboxylic acid-binding domains, lAB, 2AB and 3AB (Fig. 1) 
where n is the degree of co-operativity of the first binding sites and the dissociation constants are K4 and Kd . Other terms were defined previously. Non-linear least-squares analysis of the data yields n = 1.8.
decanedioic acid have between three and four of these loweraffinity binding sites (Table 2) . When albumin binds a single molecule of octanoic acid, the observed saturation of hexadecanedioic acid is decreased from 4.4 + 0.3 to 3.3 + 0.1 mol/mol of albumin (Table 2) . Octanoic acid has little effect on the Kd (Table 2) . Octanoic acid inhibits hexadecanedioic acid binding after the molar ratio of hexadecanedioic acid to albumin exceeds
Vol. 276 1:1, i.e. 50/tM (Fig. 4) . This suggests that octanoic acid and the secondary DCA-binding sites are in the same subdomains. In order to localize further the lower-affinity long-chain DCAbinding sites we examined the effect of competition with ligands for subdomains 2AB and 3AB. Octadecanedioic acid inhibits binding of dansylglutamine and dansylproline to subdomains 2AB and 3AB respectively (Fig. 5) . Displacement of dansylproline (3AB) is apparent at low concentrations of octadecanedioic acid. However, as shown in Fig. 5 , octadecanedioic acid does not begin to displace dansylglutamine (2AB) until the ratio of octadecanedioic acid to albumin approaches 3:1 (i.e. 15 /tM and 5,lM respectively). Double-label experiments with L-[14C]-tryptophan (which binds to subdomain 3AB) and [3H] hexadecanedioic acid demonstrate that L-tryptophan does not interfere with binding of the first molecule of hexadecanedioic acid (Fig. 6 ), which we have assigned to subdomain 2C. However, Ltryptophan does shift the Kd for binding the remaining DCA (Table 2) . We also found co-operativity between two of these lower-affinity binding sites (Fig. 6 ). Taken together, the experiments with dansylglutamine, dansylproline and L-tryptophan indicate that long-chain DCA binds in subdomains 2AB and 3AB. Moreover, the more pronounced effect of long-chain DCA on the binding of dansylproline (3AB) and the apparent shift in K4 of long-chain DCA that occurs with L-tryptophan suggests that one or two molecules of long-chain DCA are preferentially bound in subdomain 3AB and that long-chain DCA is only bound in subdomain 2AB when other sites are saturated.
Effect of acetylsalicylic acid on dicarboxylic acid binding
We examined the effect of acetylsalicylic acid on DCA binding ( Fig. 7 and Table I ) because acetylsalicylic acid has a wellcharacterized binding site in subdomain 2AB of human serum albumin (Walker, 1976) and because use of acetylsalicylic acid predisposes children to Reye's syndrome Pinsky et al., 1988) . At pH 7.4, acetylsalicylic acid acetylates several peptides, including in subdomain 2AB in human serum albumin (Walker, 1976; Hawkins et al., 1969) . At acidic pH, the degree of acetylation is reduced but both acetylsalicylic acid and salicylic acid reversibly bind to subdomain 2AB (Hawkins et al., 1968; Pinckard et al., 1970) .
The binding of dodecanedioic acid to BSA is markedly inhibited by acetylsalicylic acid (Fig. 7 and 
DISCUSSION
We proposed previously (Tonsgard et al., 1988 ) that the single higher-affinity DCA-binding site on albumin is in a subdomain that is a primary binding site for long-chain monocarboxylic acids and that low-affinity DCA-binding sites are in subdomains that bind medium-chain monocarboxylic acids and drugs (Brown & Shockley, 1982) . The current studies support those hypotheses. Progesterone, which binds in subdomain 2C (Swaney & Klotz, 1970) , competitively inhibits the binding of octadecanedioic acid.
This finding, in conjunction with previous competition studies with oleic acid, suggests that the higher-affinity long-chain DCAbinding site is in subdomain 2C. Specific probes for subdomains IC and 3C are not available to confirm this localization. Octanoic acid displaces dodecanedioic acid and hexadecanedioic acid. Displacement of DCA is not complete because octanoic acid binding is spread over three potential binding sites (lAB, 2AB and 3AB). Dodecanedioic acid and octadecanedioic acid also inhibit the binding of fluorescent probes to the drug-binding sites (2AB and 3AB).
Localization of the binding sites reveals differences in the binding of medium-chain and long-chain DCAs. The competition studies with long-chain DCAs and fluorescent probes (Fig. 5 ) demonstrate that at low DCA/albumin molar ratios long-chain DCA displaces the probe from subdomain 3AB but does not affect the binding of dansylglutamine to subdomain 2AB. Dansylglutamine is only displaced when albumin is almost saturated with DCA. In contrast, competition studies with medium-chain DCAs (Fig. 3) demonstrate that dodecanedioic acid displaces dansyl-amino acid from subdomain 2AB but has little effect on the binding of the probe to subdomain 3AB. The minor effects on binding of dansylsarcosine to subdomain 3AB may be due to conformation changes induced by the binding of dodecanedioic acid and do not suggest significant binding of the DCA in that subdomain. From these studies we conclude that long-chain DCAs bind first to the high-affinity site in subdomain 2C, and then to subdomain 3AB. As albumin becomes saturated with long-chain DCAs, an additional molecule of long-chain DCA is bound in subdomain 2AB. Medium-chain-length DCAs, however, bind exclusively to subdomain 2AB. No specific ligands for subdomain lAB are available. Therefore we cannot exclude the possibility that long-chain DCAs are bound in subdomain lAB. However, the competition experiments with L-tryptophan (subdomain 3AB) (1985) suggests that domain 3 may be able to unfold slightly in order to accommodate more than one ligand.
The competition between DCAs and acetylsalicylic acid tends to confirm the localization of the DCA-binding sites. Acetylsalicylic acid acylates Lys-199 in subdomain 2AB in human serum albumin and to a lesser extent other lysine residues (Hawkins et al., 1969; Walker, 1976) . In addition, acetylsalicylic acid and salicylic acid bind reversibly in subdomain 2AB of human serum albumin (Pinckard et al., 1970 
